TBS and BMD at the end of AI-therapy: A prospective study of the B-ABLE cohort

  1. Inicio
  2. »
  3. Sin categoría
  4. »
  5. TBS and BMD at the end of AI-therapy: A prospective...

AI therapy induces significant decreases in TBS, comparable to BMD loss. BP-treated patients maintained TBS values, whereas BMD increased. AI treatment leads to deterioration of bone microarchitecture, which seems to be attenuated by BP therapy.

Patrocinadores de la web
Lilly
Laboratorios Rubió
Grupo Italfármaco
UCB-Pharma
Theramex
Stada
Gedeon Richter
Kyowa Kirin
Amgen
Meiji Pharma
Faes Farma